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creativecommons.org/licenses/by-nc-nd/Abstract Molecular imaging using radiopharmaceuticals has a clear role in visualising the
presence and extent of tumour at diagnosis and monitoring response to therapy. Such imaging
provides prognostic and predictive information relevant to management, e.g. by quantifying
active tumour mass using positron emission tomography/computed tomography (PET/CT).
As these techniques require only pharmacologically inactive doses, age and potential frailty
are generally not important. However, this may be different for therapy involving radionu-
clides because the radiation can impact normal bodily function (e.g. myelosuppression). Since
the introduction of Iodine-131 as a targeted therapy in thyroid cancer, several radiopharma-
ceuticals have been widely used. These include antibodies and peptides targeting specific epi-
topes on cancer cells. Among therapeutic bone seeking agents, radium-223 (223Ra) stands out
as it results in survival gains in patients with castration-resistant prostate cancer and symp-
tomatic bone metastases. The therapeutic use of radiopharmaceuticals in elderly cancer pa-
tients specifically has received little attention. In elderly prostate cancer patients, there mayicine and Molecular Imaging Department, Lausanne University Hospital, Rue du Bugnon 46, CH-1011
(J.O. Prior).
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J.O. Prior et al. / European Journal of Cancer 77 (2017) 127e139128be advantages in radionuclides’ ease of use and relative lack of toxicity compared with cyto-
toxic and cytostatic drugs. When using radionuclide therapies, close coordination between
oncology and nuclear medicine is needed to ensure safe and effective use. Bone marrow reserve
has to be considered. As most radiopharmaceuticals are cleared renally, dose adjustment may
be required in the elderly. However, compared with younger patients there is less, if any,
concern about adverse long-term radiation effects such as radiation-induced second cancers.
Issues regarding the safety of medical staff, care givers and the wider environment can be
managed by current precautions.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diagnostic radiopharmaceuticals are generally phar-
macologically inactive and given only in relatively small
doses needed for imaging. Such agents are considered to
have no measurable pharmacodynamic impact [1]. For
these reasons, there is little concern about specific
toxicity problems arising with age, although the
practicalities of imaging elderly patients need to be
considered. In contrast, with therapeutic radiopharma-
ceuticals, the desired clinical benefit arises from the ef-
fects of radiation on the tumour, and courses of
treatment may involve frequent administration. In this
context, both age-related changes in tissues, such as
bone marrow, and questions of altered drug clearance
arise.
A Task Force of the International Society of Geri-
atric Oncology (SIOG) considered practical recom-
mendations on the use of radiopharmaceuticals, both
diagnostic and therapeutic, in elderly cancer patients.
This increasingly important issue has not previously
been reviewed from the perspective of elderly patients.
Such a perspective is important because physiological
reserves typically decline with age; many elderly patients
have significant comorbidities; and there is increased
risk of interactions with drugs taken for concomitant
disease [2,3].
Systemically administered therapeutic radiopharma-
ceuticals are used in thyroid cancer (an area in which
there is more than 50years of experience), in neuroen-
docrine tumours, in non-Hodgkin lymphoma and in
myeloproliferative diseases. However, these tumours are
relatively infrequent, even in the elderly.
The most common tumours (lung, colorectal, breast
and prostate), show a steeply rising incidence and
mortality with increasing age (Fig. 1) [4]. Among these
four tumours, the risk of skeletal involvement is high in
three: in advanced stages of the disease, bone metastases
are present in 47e85% of breast cancer patients,
32e60% of those with lung cancer, and 33e85% of
prostate cancer patients [5]. Given the recent increased
interest in radionuclides in patients with bone metasta-
ses from castration-resistant prostate cancer (CRPC),
and as more than 90% of them have skeletal metastases[6], discussion of the therapeutic use of radiopharma-
ceuticals focussed on this area.
The general principles underlying radionuclide use in
the elderly are likely to be similar to those in younger
patients. However, elderly patients have been under-
represented in clinical trials, despite the fact that the
majority of cancerseand hence of treatmenteis in pre-
cisely these patients. Hence, as in most areas of
oncology, specific data on the efficacy and toxicity of
radionuclides in these populations are limited.
Task Force members conducted literature searches in
their areas of expertise. We make no attempt to formally
assign levels of evidence to recommendations. They
should be considered those of an expert group and as the
basis for further discussion. The recommendation that
more elderly patients should be included in trials is an
obvious starting point.
2. Age and frailty: general considerations
While chronological ageing is uniform and relentless,
biological ageing is not. The main relevant factors are:
(1) functional losses, including those relating to cogni-
tion; (2) the effects of declining physiological reserves on
resistance to toxicity and on drug handling; and (3) the
implications of comorbidities and associated
polypharmacy.
The broad concept of frailty, defined as vulnerability
in the face of a stressor, is of interest to clinicians
assessing the likely side-effects of therapy [7]. Functional
status and the presence of comorbidities are the most
readily available guides to patients who are especially
vulnerable to adverse effects of treatment.
Means of assessing the overall fitness of elderly pa-
tients and the likely toxicity of chemotherapy have been
developed [2,8,9]. Although they have not been assessed
in the context of radiopharmaceuticals, such tools may
help predict any toxicity in elderly patients.
In the setting of prostate cancer specifically, a recent
International Society of Geriatric Oncology (SIOG)
Task Force [3] has advocated initial screening for
cognitive impairment, to establish patient competence in
making decisions, followed by brief evaluation of health
status using the validated G8 screening tool. Abnormal
Fig. 1. (A) Incidence and (B) mortality of the three most frequently encountered cancers in Europe in men and women according to age
(Data from [http://globocan.iarc.fr GLOBOCAN 2012, last accessed on September 2014, 21], IARC).
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assessment that evaluates comorbid conditions,
dependence and nutritional status (by estimation of
weight loss).
Also in the prostate cancer setting, the potential
importance of comorbidities is illustrated by the trial in
which D’Amico et al. randomised 206 men to radio-
therapy (RT) alone or RT plus androgen suppression
[10]. For the group as a whole, combined treatment was
associated with significantly reduced all-cause mortality
(30 versus 44 deaths, p Z 0.01). However, among men
with moderate or severe comorbidity, there was a trendin the opposite direction with more deaths in the RT
plus androgen suppression group than in those treated
with RT alone (19 versus 13 deaths, p Z 0.08). While
acknowledging that they derive from a subgroup anal-
ysis, such data make a strong case for distinct trials to be
conducted in patients with comorbidities.
Most radiopharmaceutical studies do not include
specific measures of comorbidity, frailty or functional
loss. In their absence, the potential impact of such
agents on less fit patients must be extrapolated from the
healthier patients who were enrolled, or from studies of
other agents which did include less fit patients.
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3.1. Diagnosis and staging
The availability of information from radionuclide im-
aging contributes greatly to personalised cancer treat-
ment. Here, we do not seek to compare the merits of
different imaging techniques, but consider them from
the perspective of the elderly.
In elderly Medicare patients (mean age 73years),
analysis of registry data from more than 20,000 imaging
studies demonstrated that having information from-
fluorine-18- fluorodeoxyglucose (18F-FDG) positron
emission tomography computed tomography (PET-CT)
led to a major change in management in 30e40% of
cases and a minor change in another 10e30% [11]. The
report covered the role of imaging in diagnosis, staging,
restaging and investigation for suspected recurrence and
monitoring response to therapy. It concluded that phy-
sicians frequently change their intended management of
elderly cancer patients on the basis of PET scans, and
that this applies across the range of its uses. However, it
is notable that only 5% of patients in the study were
aged 85years or more.
Other important applications include guiding and
selecting biopsy sites, identifying tumours in patients
with rising markers, guiding radiation therapy, and
distinguishing tumour recurrence or residual tumour
from post therapy changes (such as fibrosis and necro-
sis) on CT.
In several tumours, imaging with a variety of radio-
pharmaceuticals is an integral part of diagnosis.
Although extremely rare, adverse allergic reactions have
been reported with 18F-FDG [12e14]. Overall, however,
diagnostic nuclear medicine is associated with an
exceptionally low risk of toxicity as, at the dose
administered, the agents are not pharmacodynamically
active. In a prospective questionnaire study conducted
over 4years covering 80,000 radiopharmaceutical ad-
ministrations for PET in 22 participating institutions,
Silberstein found no reports of adverse reactions [15]. In
an earlier 5-year prospective study in 18 institutions,
only 18 adverse reactions were recorded in more than
780,000 radiopharmaceutical administrations [16]. Of
these reactions, ten were rashes. None of the patients
involved required hospitalisation or had significant
sequelae.
Use of diagnostic radiopharmaceuticals does not
require assessment of renal insufficiency; and although
diabetic patients should have a glucose level that is well
controlled on the day of the 18FDG PET, comedication
with metformin is not a potential problem. In both
cases, this situation is different from that with CT
involving contrast media.
In general, no clinically relevant issues arise relating
to the particular vulnerability of elderly patients, nor tothe increased risk of drug interaction or toxicities related
to comorbidities. Furthermore, compared with children
and young adults, the long-term risks for radiation-
induced second cancers associated with radiation expo-
sure due to diagnostic medical procedures are unlikely
to be relevant in elderly patients with more limited life
expectancy.
However, there are certain practical considerations
relating, for example, to technetium-99m-
bisphosphonate bone scintigraphy, which is still the
standard method of staging in advanced prostate cancer
[17,18]. Although safe, the length of time that may be
required for scanning can be difficult for elderly pa-
tients, especially for those with musculoskeletal prob-
lems who find prolonged immobility uncomfortable and
even painful. In frail elderly patients, it is worth
considering an increase in the dose of isotope adminis-
tered to allow shortening of the scanning time, thereby
minimizing patient discomfort.
3.2. Prognosis and treatment monitoring
Prognosis is of concern with all patients but is particu-
larly relevant to the elderly in whom expected benefits
and toxicity must be balanced in the light of concomi-
tant disease and competing causes of death. Information
from radionuclide scanning can contribute considerably
to management decisions. If used appropriately, it may
avoid the need for other investigations, as well as un-
necessary treatment. Such an outcome is desirable for
reasons of patient comfort, quality of life and cost.
The quantification of overall tumour load and, more
importantly, of biologically aggressive tumour is rele-
vant to a variety of cancers. However, whether or not it
is a predictor of poor outcome depends on the tumour
type and on the treatments available. In colorectal and
squamous cell lung cancer, a high standardised uptake
volume (SUVmax) suggests poor prognosis [19]. Quan-
titative analysis of FDG PET has value in predicting
relapse-free (RFS) and overall survival (OS) indepen-
dently of tumour-node-metastasis (TNM) staging in
non-small cell lung cancer [20]. Also, in lymphoma
FDG-PET has become a standard imaging method for
therapy monitoring, providing prognostic and predictive
information. A computer programme to aid such
quantification is being developed to calculate its pre-
dictive value [21].
FDG PET can identify previously unknown second
primary tumours (which are present in about 1e2% of
patients) or distant metastases (Fig. 2), as in head and
neck cancer [22]. Knowing their presence may influence
the timing and aggressiveness with which the initial or
primary cancer is treated.
FDGPET also allows identification of patients who
fail to respond to initial cycles of neoadjuvant chemo-
therapy. Such techniques seem especially useful in
Fig. 2. A 69-year old patient with biochemical relapse from
prostate cancer (Gleason 7, PSA3 ng/ml) showing a single site of
bone metastasis on the right ischium with 18F-choline PET not
visible by bone scintigraphy. The patient received isolated radia-
tion therapy and the PSA decreased to <0.05 ng/ml). He has been
relapse-free for 24 months.
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agus, bladder and lung [23e27].
Other radiopharmaceuticals are relevant to a specific
cancer-related process. Use of fluorine-18-FLT, aTable 1
Concerns about radiopharmaceuticals in diagnosis, monitoring and therap
Diagnosis and m
including for re
Age-related alterations in pharmacokinetics or
pharmacodynamics resulting in reduced efficacy
or increased toxicity
For FDG, chec
glucose levels
Interaction with drugs being taken for comorbid
conditions
None
Effects on reproductive function, foetal toxicity and
breast feeding
Not applicable
Risk of long-term radiation toxicities such as
induction of treatment-related solid and
haematological cancers
None
Fluorodeoxyglucose (FDG); radium-233 (223Ra); 131I-metaiodobenzyleguamarker for tumour cell proliferation, can be valuable
e.g. in monitoring the treatment of lymphoma or the
effectiveness of radiotherapy and in adjusting the
treated volume [28,29].
Such adaptive radiation therapy allows treatment to
be confined to a smaller area at increased dose when a
tumour has been reduced in size, or stopped or changed
in those who are clearly not responding [30]. Table 1.
In castration-resistant prostate cancer (CRPC) pa-
tients on systemic treatment, current European Society
for Medical Oncology (ESMO) guidelines recommend
regular imaging to monitor disease response or pro-
gression, although their recommendation is supported
by a relatively low level of evidence (V) [31]. At the time
of writing, the latest European Association of Nuclear
Medicine (EANM) guidelines were still in preparation.
FDG PET CT scan is not recommended for prostate
cancer except for aggressive form of disease, while bone
scan using 99mTc-labeled diphosphonates is still
standard [18].
Techniques such as sodium 18F PET-CT may prove
valuable in relation to 223Ra treatment [32]. At present,
a standard bone scan is still routine to select eligible
patients. In the individual patient, and in the absence of
trial evidence, practice in relation to imaging should be
guided by factors such as the goal of treatment, pros-
tate-specific antigen (PSA) increase and velocity, and
clinical suspicion.
Newer agents targeting the prostate-specific mem-
brane antigen (PSMA) are being developed and used
clinically based on 68Ga and 18F radioisotopes and have
already been shown superior to choline-labeled tracers.
These are likely to develop further and play a significant
role in CRPC [33,34].
In Europe, gallium-68 (Ga-68)-PSMA-11 PET/CT
(PSMA PET/CT) is increasingly used and provides
sensitivity and specificity superior to that of F-18-FCH,
although it is not yet approved by the European Med-
icines Agency (EMA). The technique has potential as a
means of triaging patients to be treated by Ra-223 or
lutetium-177 (Lu-177)-PSMA [35]. 11C- or 18F-choline
radiopharmaceuticals have proved useful in detectingy and their potential relevance to the elderly cancer patient.
onitoring,
lapse
Therapy
k Minor for 223Ra, which is excreted predominantly in
faeces. But renal function is relevant for other
therapeutic radionuclides
Minor, though certain beta-blockers, for example,
decrease MIBG targeting
Not applicable
Less concern in elderly populations than in younger
patients
nidine (MIBG).
Table 2
Summary of current recommendations relevant to use of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).
Source Setting Recommendations Evidence level grade Reference
ESMO First line in mCRPC
Second line (post docetaxel)
Docetaxel
For asymptomatic or mildly symptomatic disease:
abiraterone, enzalutamide
or sipuleucel-T
For bone predominant, symptomatic disease without visceral
metastases: 223Ra
Abiraterone, cabazitaxel, enzalutamide, and 223Ra (in those
without visceral disease)
I A
I A
II B
I A
I A
Parker et al., 2015 [31]
European Association
of Urology
Candidates for cytotoxic therapy
Relapse following docetaxel
No clear-cut recommendation can be made for the most
effective drug for secondary treatment (i.e. hormone therapy
or chemotherapy)
Offer docetaxel 75 mg/m2 every 3 weeks.
Offer further life-prolonging treatment options, which include
cabazitaxel, abiraterone, enzalutamide and radium-223.
Base second-line treatment decisions on pre-treatment
performance status, comorbidities and extent of disease.
3 A
1a A
1a A
B
Mottet et al., 2016 [54]
Non-specific management In painful bone metastases, palliate early using
radionuclides, external beam radiotherapy and analgesics
1a B
NCCN Initial therapy:
No visceral metastases
Visceral metastases
Subsequent systemic therapy:
No visceral metastases
Visceral metastases
Abiraterone, docetaxel, enzalutamide, or 223Ra (for
symptomatic bone mets); or clinical trial; or secondary
hormone therapy
Docetaxel, enzalutamide; or abiraterone, or mitoxantrone
(if not candidate for docetaxel); clinical trial; or secondary
hormone therapy
For patients with prior exposure to docetaxel, 223Ra is
among the 10 options (including docetaxel re-challenge and
best supportive care); for patients with prior enzalutamide
or abiraterone, 223Ra is among eight options
223Ra not among the options
Cat. 1
Cat. 1
Cat. 1
NCCN.org v2.2016 [56]
American Urological
Association
Symptoms related to bony
metastases; no known visceral disease
No prior docetaxel
Prior docetaxel
223Ra an option in patients with good PS;
also an option in selected poor PS patients when PS is
directly related to symptoms related to bone mets.
223Ra an option in good PS patients
Standard
Expert opinion
Standard
AUA 2015 [57]
American Society of
Clinical Oncology No prior docetaxel
Prior docetaxel
Continue androgen deprivation indefinitely
Offer abiraterone, enzalutamide or 223Ra; may also offer
docetaxel/prednisone accompanied by discussion of toxicity
risk; and sipuleucel-T if no or minimal symptoms.
May offer cabazitaxel with toxicity discussion; or
mitoxantrone with discussion of limited benefit and toxicity
risk.
Benefit of 223Ra moderate;
harm low; evidence strong;
recommend-ation strong
Basch E et al., 2014 [58]
PS: performance status NCCN: National Comprehensive Cancer Network.
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example is shown in Fig. 2.
4. Therapeutic radiopharmaceuticals
Age-related dose adjustment is generally not required. If
necessary, anaemia should be corrected as part of gen-
eral supportive care. There are no guidelines specific to
the need for transfusions in the haematopoietic support
of patients being treated with radiopharmaceuticals.
Transfusion should therefore be used at the physician’s
discretion.
The use of phosphorous-32 (32P) in refractory
myeloproliferative diseases such as polycythaemia vera
and essential thrombocythaemia should also be
acknowledged. Although overshadowed by recent de-
velopments, 32P is well tolerated and can be particularly
helpful in elderly patients in whom one or two doses
provide adequate disease control. In short, established
drugs may work well, and especially so in patients with
limited life expectancy.
In solid tumour oncology, the archetypical targeted
radiopharmaceutical is 131I for the treatment of differ-
entiated thyroid cancer following thyroidectomy. The
safety and efficacy of this treatment in both adjuvant
and metastatic settings are well established and thor-
oughly discussed elsewhere [36]. In relation to the
elderly, it is worth noting that it may be preferable to
raise thyroid stimulating hormone (TSH) levels by in-
jection of recombinant TSH (rTSH) (Thyrogen) pre-
treatment rather than by thyroid hormone withdrawal.
This avoids a prolonged period of hypothyroidism and
the associated risks of depression and reduced meta-
bolism and activity, which may be especially harmful in
the elderly. However, this approach is not approved in
all countries, and the number of rTSH administrations
may be restricted to two in addition to the initial
treatment.
Although this article relates mostly to solid tumours,
radioimmunotherapy contributes to the treatment of
haematological malignancies. Most attention has
focussed on CD20-positive non-Hodgkin lymphoma
(NHL). Although effective in subgroups of patients, this
treatment option is not widely used. In their 2005 review
[37], Rao et al. concluded that these agents are well
tolerated in elderly NHL patients, even though marrow
involvement is common. Caution is required if more
than 25% marrow is involved, in case of prior marrow-
ablative therapy or hypocellular bone marrow (<15%).
There is also evidence for the efficacy of 90Y resin
microspheres in the radioembolisation of patients with
advanced hepatocellular carcinoma [38]. This may have
particular relevance in elderly patients needing to avoid
chemotherapy. In a pan-European series of 325 patients
treated by this method, the mean age was 65years
(range 22e87). However, the administration of 90Y mi-
crospheres and of 131I-lipiodol is invasive as it involvesselective hepatic artery injection. Shunting to the lungs,
normal liver and/or stomach may result in clinically
significant short-term radiation burden (inducing pneu-
monitis, hepatitis or stomach ulceration). This may be
particularly relevant in elderly patients with reduced
pulmonary or liver function and potential additional
gastric toxicity arising from concomitant medication.
An interesting application of radioembolisation is in
the treatment of early-stage disease with a curative
intent, given that 90% of yttrium-90 resin microspheres
(90Y)-treated tumours less than 3 cm and two-thirds of
tumours of 3e5 cm show complete pathological necrosis
(so-called radiation segmentectomy) [39]. Additionally,
it has been observed that treatment of a lobe results in
atrophy of that lobe and hypertrophy of the contralat-
eral one, a characteristic that may aid in resection [40].
When considering a patient for radioembolisation,
the tumour stage, liver function, renal function, per-
formance status, a-fetoprotein level, coagulation
parameters and goals of treatment must be taken into
consideration. This is most reliably achieved through a
multidisciplinary board.
Patients with poor hepatic reserve are less likely to
tolerate a whole liver treatment. Other patients at high
risk include those with disease affecting >50% of the
liver, albumin less than 30 g/l (3 mg/dl), or bilirubin
greater than 34.2 mmol/l (2 mg/dl) [41]. Patients with
impaired pulmonary status should also be examined
carefully, because a significant lung shunt fraction is
more likely to cause life-threatening radiation pneumo-
nitis. Prior external beam radiation therapy is also
considered a contraindication.
Radiopharmaceuticals are also being used with good
palliative effect in metastatic or unresectable neuroen-
docrine tumours. These agents target either the
noradrenaline transporter (in the case of 131I-MIBG) or
somatostatin receptor subtypes overexpressed on
tumour cells using 90Y linked to the somatostatin ana-
logues octreotide or octreotate (90Y-DOTATOC and
-DOTATATE). With the latter agents, which accumu-
late in the renal cortex, renal toxicity is a concern, as is
thrombocytopenia due to bone marrow toxicity. How-
ever, a study of more than 500 patients treated with
DOTATATE found few adverse events (AEs) [42]. A
recent review concluded that, while mild haematological
toxicity with the two agents was common, renal toxicity
was rare [43]. However, the mean age of the patients was
57years (range not given), so the impact on elderly,
frailer patients has not been established.
4.1. Bone-seeking agents
In relation to more prevalent cancers, the frequent
occurrence of osseous metastases in advanced disease
has focussed attention on the potential of bone
metastasis-seeking radiopharmaceuticals. Of these,
89strontium, and 153samarium-ethylenediamine tetra
J.O. Prior et al. / European Journal of Cancer 77 (2017) 127e139134(methylene phosphonic acid) [EDTMP] emit be parti-
cles (electrons) with a few millimetre range and a rela-
tively limited biological effect (Table 3.). The alpha
emitter 223Ra, on the other hand, has effects that are
confined to a few cell diameters (<0.1 mm) but are more
powerful. Whereas a be (electron) emitter may require
more than a thousand DNA hits to achieve cell kill, this
effect is achieved with only 1e4 hits from an alpha
emitter. The fact that radiation damage is confined to
the 40e100 mm area immediately surrounding 223Ra
molecules, rather than up to 12 mm with be emitters,
suggests a reduced likelihood of adverse effects on
nearby bone marrow.
While 89strontium and 153samarium-EDTMP have
proven valuable in the relief of pain due to bone me-
tastases in metastatic castration-resistant prostate can-
cer (mCRPC), 223Ra has been shown in robust phase III
studies to result in improved overall survival. Other
radiopharmaceuticals have not been shown to have this
effect [44]. Hence 223Ra is a therapy to be considered
alongside abiraterone or enzalutamide. In addition to its
role in prolonging survival, the agent may provide
effective pain relief.
Although important for all patients, patient prefer-
ence is particularly relevant to the elderly in whom
quality of life (QoL) is preeminent. In this context, it is
worth noting that strontium-89 has been associated with
well-maintained QoL in metastatic CRPC, and 223Ra
with improved QoL relative to placebo in the same
setting [45,46]. There is a general reluctance to undergo
chemotherapy if there are less toxic alternatives, and
elderly patients may trade slightly reduced efficacy for
higher quality of life or less risk of AEs. In metastatic
CRPC, the almost simultaneous advent of life-
prolonging androgen receptor targeting agents, immu-
notherapy, a novel taxane and a new radiopharmaceu-
tical poses acute questions about the optimal sequencing
and potential combination of treatments [31].
Use of therapeutic radiopharmaceuticals such as
223Ra in the elderly, as in younger patients, is clearlyTable 3
Physical and clinical characteristics of therapeutic radiopharmaceuticals in
Agent T 1/2 d Tissue penetration
max (mean) mm
Standard
dose
Efficacy
Strontium 50.5 5.5 (2.4) 148 MBq Pain reduction: 3
4e28 d; no OS b
Samarium 1.9 2.5 (0.6) 37 MBq/kg Pain relief in 83%
e38% no OS be
Radium 11.4 <0.1 50 kBq/kg Significantly incr
control group (1
significantly long
event (15.6 versufeasible. Given patients’ more limited life expectancy,
long-term toxicities, notably the risk of inducing a sec-
ond cancer, are of less (if any) concern. This raises the
question of whether their use in elderly patients should
be governed by regulations less stringent than those
applicable to the treatment of younger adults.
Risk of short term toxicities arising from damage to
the kidneys and bone marrow may be exacerbated by
reduced renal and marrow reserves. However, as treat-
ment is fractionated over six cycles one month apart,
radiation exposure on each occasion is one sixth or less
of the maximum tolerated dose. Even so, there is the
possibility that prior treatment with radiopharmaceuti-
cals may mean that subsequent chemotherapy is less well
tolerated, raising issues of optimal sequencing. Age,
especially in combination with poor performance status
(PS), is considered a risk factor for febrile neutropenia
[47].
In the ALSYMPCA trial, 600 patients with CRPC
were treated with 223Ra and toxicities were generally
mild [48]. The most frequentlyreported side-effects,
occurring in more than 10% of patients, were anaemia,
thrombocytopenia, constipation, nausea, diarrhoea,
vomiting, fatigue, weight loss, anorexia, bone pain and
peripheral oedema.
Grade 3e4 anaemia was reported in 13% of 223Ra-
treated patients, but this rate was not significantly
different from that with placebo. anaemia seemed
related to extensive disease rather than treatment-
related; and patients experiencing anaemia did not suffer
more than others from side-effects. Grade 3 or 4
thrombocytopenia occurred in 6% of 223Ra-treated pa-
tients. One death from thrombocytopenia was reported.
The fall in platelets seemed related to treatment, as it
was less frequent with placebo, occurring in only 2% of
patients. However, the 6% rate seen in patients receiving
223Ra was still low. Grade 3e4 neutropenia occurred in
3% of treated patients.
It should be noted that certain toxicities associated
with 223Ra are of particular concern in the elderly. Theycurrent use for prostate cancer.
Toxicity
3% CR; time to response
enefit
Leucopenia in 20e80% and
thrombocytopenia in 30e80% (both
reversible); minimal anaemia
of pts, complete in 31
nefit
Reversible leucopenia in 40e50% of pts
and thrombocytopenia in 20e42%
eased OS compared with
4.9 versus 11.3 months);
er time to first skeletal
s 9.8 months)
Grade 3e4 anaemia in 13% of 223Ra-
treated patients was not significantly
different from placebo. Gr 3e4
thrombocytopenia in 6% of treated
patients versus 2% with placebo.
Occasional cases of fatigue, nausea and
loose stools; but toxicities in general are
comparable with placebo.
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effect, leading to dehydration and possible kidney
damage and other sequelae such as confusion and elec-
trolyte disturbance; anaemia is less well-tolerated; and
thrombocytopenia may be a particular problem in pa-
tients on anticoagulants.
The EMA-approved label for 223Ra indicates that
there are limited data on patients with moderate renal
impairment, and no data on severe impairment or end-
stage renal disease; and safety has not been studied in
patients with hepatic impairment. However, as 223Ra is
not cleared through the kidneys, nor metabolised by the
liver or eliminated via the bile, renal or hepatic impair-
ment are not expected to affect its pharmacokinetics.
5. Radiopharmaceuticals in prostate cancer
Prospective phase III data in metastatic CRPC support
the first-line use of docetaxel, enzalutamide and abir-
aterone (all of which significantly extend OS) and of
sipuleucel-T and 223Ra. These latter agents also extend
OS but their pivotal trials also included patients who
had had prior chemotherapy (though in the case of the
sipuleucel-T trial, they amounted only to 15%) [49e53].
Second line, there are prospective data only for patients
who had had prior docetaxel.
With regard to 223Ra, the ALYSMPCA trial included
patients with CRPC metastatic to bone [48]. Fifty-seven
percent had received prior docetaxel. The chemo-naı¨veFig. 3. Example of bone scintigraphic response in a 72-year old patien
bone metastases (A) in the skull, right hemi-jaw, left shoulder, ribs, t
6months.subgroup was not clearly defined and included patients
unfit for chemotherapy, those unwilling to undergo
it and those without access to it. Patients with visceral
metastases and bulky lymph node disease were excluded.
Table 2 summarises current recommendations rele-
vant to use of radiopharmaceuticals in mCRPC.
Of note, the 2016 European Association of Urology
(EAU) guidelines on prostate cancer contain a section
specific to management of the disease in elderly men,
which should be undertaken by a multidisciplinary team
[54]. In accord with the SIOG working group on pros-
tate cancer [55], the EAU recommends use of the G8
screening tool for initial assessment of health status,
followed when appropriate by full, specialist geriatric
assessment to determine the reversibility of any im-
pairments. Subsequent management should be based on
an elderly patient’s individual health status.
The role of newlydevelopedagents formCRPChasnot
beenwell defined in elderlymen specifically. However, the
relative ease of administering 223Ra (i.v. every 4weeks)
and the fact that it seems generally well tolerated and does
not interact with comedicationmaymake it a good option
in elderly patients, especially those with multiple comor-
bidities (Fig. 3). It would be of great help to randomise the
new CRPC agents against each other in a trial specifically
designed to include elderly patients and with a focus on
quality of life and patient-reported outcomes.
When any of these recommendations go beyond
existing data, they are phrased with caution, as ist with metastatic castration-resistant prostate cancer and multiple
horacic and lumbar spine and (B) after six courses of 223Ra over
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Use of radiopharmaceuticals is cited as one of several
options, but 223Ra is linked to the presence of symp-
tomatic bone metastases and the absence of visceral
involvementewhich implies that clinicians must look for
such disease. Although PS is a factor in the AUA
management plan, none of the recommendations is age-
specific or accounts for age-associated factors such as
comorbidities and frailty.
The NCCN suggests that estimation of remaining life
expectancy is critical to informed decision making about
disease management and recommends that clinicians
consult the actuarial life tables. For patients judged to
be in the best quartile of overall health, 50% should be
added to the given life expectancy for age; and for pa-
tients in the poorest quartile, 50% should be deducted.5.1. Guidance from trial data related to age
The pivotal trials mentioned above differ in their in-
clusion and exclusion criteria with respect to factors
such as PS, the presence of visceral metastases and
whether or not patients had received prior docetaxel.
Within the recommendations, there is a certain amount
of age-related evidence to guide choice of an agent for
elderly patients. With docetaxel, the OS benefit in pa-
tients aged 75years and in patients aged 65years and
above is similar to that in the wider population studied
[49]. Forty percent of elderly patients had grade 3e4
AEs, and there was a greater need for dose reduction.
In the pivotal, placebo-controlled enzalutamide trial,
35% of enrolled patients were aged 75 or more [59]. The
PFS and OS benefits of treatment were significant both
in this age group and in younger patients. Similarly, in
the pivotal trial versus mitoxantrone, the OS benefit of
cabazitaxel was similar across prespecified subgroups,
including patients aged 65 and above.
Table 3 shows the physical characteristics and clinical
outcomes of currently available radiopharmaceuticals.
In the ALSYMPCA trial in men with CRPC and
symptomatic bone metastases, the median age of pa-
tients enrolled was 71, and 28% were aged over 75years
[48]. The mean haemoglobin level of patients included
was 12.2 g/dl, which seems higher than expected in
routine practice for this patient population; and no data
are given about comorbidities or geriatric functional
assessment.
It is not clear how many of the patients who did not
have prior docetaxel had refused chemotherapy, how
many were judged unfit for chemotherapy, and how
many had no access to it. It is therefore difficult to judge
the efficacy and safety of this treatment in elderly pa-
tients. In the poorer PS group, the 0.73 HR for OS was
in the same positive direction as for the population as a
whole. However, the benefit of treatment did not achieve
statistical significance; and, as with any subgroupanalysis, this finding can be considered only as hy-
pothesis generating.5.2. Protection and safety when using therapeutic
radiopharmaceuticals
Protecting hospital staff, the general public and the
environment from unnecessary exposure to radiation is
a major concern in radiopharmaceutical diagnostics and
therapy. Relevant regulations differ considerably from
one country to another. For example, there have been
concerns in Germany about the possibility of exhaled
radon. Swiss patients given 223Ra have to accept that
cremation must be postponed (or burial used instead) if
they die within seven days of its administration. Nuclear
medicine physicians and technicians need to check
which are applicable to the place they practice.
Elderly patients are more likely than their younger
counterparts to require urgent surgery for conditions
unrelated to cancer. In any patient with bone metasta-
ses, there is the possibility that fracture or spinal cord
compression will necessitate surgical intervention. More
generally, a patient’s overall functional status e espe-
cially possible incontinence e is an age-related factor
that is clearly relevant to radioprotection.
Appropriate radioprotection advice should be avail-
able to hospital staff when required in managing a pa-
tient recently treated with a radiopharmaceutical
(protective eyewear for operating theatre staff and
double pairs of gloves, for example, would be
appropriate).6. Discussion and conclusions
The use of radiopharmaceuticals to accurately image the
spread of disease is of proven value. They are also likely
to be useful in quantifying the burden of metabolically
active tumour, which will further aid in personalising
treatment. In relation to the elderly patient with signif-
icant comorbidities and limited life expectancy, the
prognostic information such imaging could provide
would be particularly valuable in enabling them to avoid
unnecessary treatment and preserve quality of life.
When attempting to make recommendations for the
elderly, it is striking to find that so few elderly patients
have been entered into pivotal clinical trials, even of
targeted anticancer agents [60]. In an ideal world, the
proportion of elderly patients included in a trial would
match the proportion of those with the disease. In the
real world, there may be a case for providing companies
with incentives to enrol such patients in key studies, or
with requiring them to conduct trials specifically in the
elderly, those who have comorbidities and those who are
frailer [61].
The 50-year history of 131I in thyroid tumours should
give us confidence that radiopharmaceuticals can safely
Table 4
Take-home messages.
 Include more elderly patients in pivotal clinical trials; this applies also to targeted anticancer agents
The underrepresentation of elderly cancer patients in pivotal clinical trials restricts our ability to tailor management to their specific
circumstances (comorbidities and frailty)
 Diagnostic radiopharmaceuticals are not an issue of particular concern in elderly patients, even in the presence of vulnerability
Consider increasing isotope dose activity to decrease scan time and so minimise patient discomfort
 Therapeutic radiopharmaceuticals in elderly patients with hormone-resistant prostate cancer and symptomatic metastases are safe but
require
 assessment of short-term toxic effects on bone marrow and
 adequate information to be given to patients, family members and care staff
 More studies are needed on the combination of therapeutic radiopharmaceuticals with chemo- and/or other systemic therapies to
determine if increased clinical benefit can be achieved with acceptable additional toxicity
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patients. However, with each new radioisotope and
indication come unquantified risks. This applies both to
the patients treated and to the staff treating them. In the
elderly prostate cancer patient with symptomatic bone
metastases and a life expectancy of less than 5years, it is
very unlikely that long-term effects of radiation expo-
sure will become apparent. In a young woman with
breast cancer, this is not necessarily the case. However,
both kinds of patient must be assessed for the risk of
short-term toxic effects, for example to bone marrow or
the kidney. And staff administering radiopharmaceuti-
cals are understandably concerned about the potential
long-term impact of radiation on their general health
and wellbeing, including fertility. Both patients and staff
should be fully informed and given written information
about risks.
Bone-seeking radiopharmaceuticals have no role in
preventing the development of visceral metastases.
While the risk of such involvement is initially low in
prostate cancer, almost 50% of patients develop them at
later stages of disease, and, with the prolongation of
survival following the introduction of new drugs, this
proportion is likely to increase [62]. Studies to assess
whether the use of radiopharmaceuticals in combination
with chemo- and other systemic therapies will increase
clinical benefit with acceptable additional toxicity are
now being conducted.
Since the relative costs of individual agents vary
greatly from one health system and country to another,
it is difficult to include such factors in clinical recom-
mendations. However, the availability and cost of
different agents are clearly relevant to the making of
therapeutic decisions in the everyday management of the
elderly, as with all cancer patients. Table 4.
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